Edited Books

• Talley, N., Segal, I., Weltman, M. (2008). Gastroenterology and Hepatology: a clinical handbook. Australia: Elsevier.

Book Chapters

• Weltman, M., Phung, N. (2011). Rectal/perianal mass and colorectal cancer. In N. J. Talley (Eds.), Clinical Gastroenterology, 3rd Edition, (pp. 279-292). Australia: Elsevier.
• Weltman, M., Phung, N. (2011). Vomiting blood, stack stools, blood per rectum, occult bleeding. In N. J. Talley (Eds.), Clinical Gastroenterology, 3rd Edition, (pp. 115-129). Australia: Elsevier.
• Milne, B., Bell, J., Weltman, M., Lampropoulos, B., Towns, S. (2009). Alcohol, drugs and Australian young people. In Bennet, D; Towns, S; Elliot, E; Merrick, J. (Eds.), Challenges in Adolescent Health: An Australian Perspective, (pp. 163-175). United States: Nova Science Publishers.
• Weltman, M., Darke, J. (2008). Acute liver failure. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 491-501). Australia: Elsevier.
• Weltman, M. (2008). Obesity and Abnormal Liver Function Tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 411-420). Australia: Elsevier.
• Weltman, M. (2008). Occult gastrointestinal bleeding and iron deficiency anemia. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 246-259). Australia: Elsevier.

Journals

• Nicoll, A., Roberts, S., Lim, R., Mitchell, J., Weltman, M., George, J., Wigg, A., Stuart, K., Gow, P., MacQuillan, G., Strasser, S., et al (2019). Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Alimentary Pharmacology and Therapeutics, 49(10), 1314-1322. [More Information]
• Cunningham, E., Amin, J., Feld, J., Bruneau, J., Dalgard, O., Powis, J., Hellard, M., Cooper, C., Read, P., Weltman, M., et al (2018). Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. International Journal of Drug Policy, 62, 14-23. [More Information]
• Roberts, S., Lim, R., Strasser, S., Nicoll, A., Gazzola, A., Mitchell, J., Siow, W., Khoo, T., Hamarneh, Z., Weltman, M., George, J., et al (2018). Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. Clinical Gastroenterology and Hepatology, 16(2), 268-277. [More Information]
• Mayo, M., Wigg, A., Leggett, B., Arnold, H., Thompson, A., Weltman, M., Carey, E., Muir, A., Ling, L., Rossi, S., et al (2018). NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Hepatology Communications, 2(9), 1037-1050. [More Information]
• Cunningham, E., Hajarizadeh, B., Dalgard, O., Amin, J., Hellard, M., Foster, G., Bruggmann, P., Conway, B., Backmund, M., Weltman, M., et al (2017). Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infectious Diseases, 17(1), 1-12. [More Information]
• Midgard, H., Hajarizadeh, B., Cunningham, E., Conway, B., Backmund, M., Bruggmann, P., Bruneau, J., Bourgeois, S., Dunlop, A., Weltman, M., et al (2017). Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International Journal of Drug Policy, 47, 230-238. [More Information]
• Grebely, J., Dalgard, O., Cunningham, E., Hajarizadeh, B., Foster, G., Bruggmann, P., Conway, B., Backmund, M., Robaeys, G., Weltman, M., et al (2017). Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. International Journal of Drug Policy, 47, 177-186. [More Information]
• Jideh, B., Weltman, M., Wu, Y., Chan, C. (2017). Esophageal squamous papilloma lacks clear clinicopathological associations. World Journal of Clinical Cases, 5(4), 134-139. [More Information]
• Eslam, M., McLeod, D., Kelaeng, K., Mangia, A., Berg, T., Thabet, K., Irving, W., Dore, G., Sheridan, D., Gronbaek, H., Booth, D., Weltman, M., Douglas, M., Liddle, C., George, J., et al (2017). IFN-(lambda)3, not IFN-(lambda)4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nature Genetics, 49(5), 795-800. [More Information]
• Cropley, A., Weltman, M. (2017). The use of immunosuppression in autoimmune hepatitis: A current literature review. Clinical and Molecular Hepatology, 23(1), 22-26. [More Information]
• Eslam, M., Mangia, A., Berg, T., Chan, H., Irving, W., Dore, G., Abate, M., Bugianesi, E., Adams, L., Najim, M., Weltman, M., Rahme, A., Booth, D., Liddle, C., Douglas, M., van der Poorten, D., George, J., White, R., Leung, R., et al (2016). Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 64(1), 34-46. [More Information]
• Eslam, M., Hashem, A., Romero-Gomez, M., Berg, T., Dore, G., Mangia, A., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Kelaeng, K., Ahlenstiel, G., Liddle, C., Douglas, M., Booth, D., George, J., et al (2016). FibroGENE: A gene-based model for staging liver fibrosis. Journal of Hepatology, 64(2), 390-398. [More Information]
• O'Connor, K., Read, S., Wang, X., Schibeci, S., Eslam, M., Ong, A., Weltman, M., Douglas, M., Mazzola, A., Craxi, A., Stewart, G., Liddle, C., George, J., Ahlenstiel, G., Booth, D., et al (2016). IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes and Immunity, 17(6), 328-334. [More Information]
• Jideh, B., Keegan, A., Weltman, M. (2016). Lymphocytic esophagitis: Report of three cases and review of the literature. World Journal of Clinical Cases, 4(12), 413-418. [More Information]
• Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., Irving, W., Berg, T., Dore, G., Gronbaek, H., Sheridan, D., Weltman, M., White, R., Douglas, M., Liddle, C., van der Poorten, D., George, J., Eslam, M., et al (2016). MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 7, 1-8. [More Information]
• Jideh, B., Chen, H., Weltman, M., Chan, C. (2016). Metastatic periampullary clear cell renal carcinoma. Gastrointestinal Endoscopy, 83(5), 1040-1042. [More Information]
• Grebely, J., Alavi, M., Micallef, M., Dunlop, A., Balcomb, A., Phung, N., Weltman, M., Day, C., Treloar, C., Bath, N., Haber, P., et al (2016). Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study. Addiction, 111(2), 311-319. [More Information]
• Fragomeli, V., Weltman, M. (2015). Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care. Journal of Gastroenterology and Hepatology, 30(Suppl 2), 6-11. [More Information]
• Kemp, W., Levy, M., Weltman, M., Lubel, J. (2015). Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. Journal of Gastroenterology and Hepatology, 30(3), 453-462. [More Information]
• Koloski, N., Jones, M., Weltman, M., Kalantar, J., Bone, C., Gowryshankar, A., Walker, M., Talley, N. (2015). Identification of early environmental risk factors for irritable bowel syndrome and dyspepsia. Neurogastroenterology and Motility, 27(9), 1317-1325. [More Information]
• Eslam, M., Hashem, A., Leung, R., Romero-Gomez, M., Berg, T., Dore, G., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Douglas, M., Liddle, C., Booth, D., George, J., Ahlenstiel, G., et al (2015). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 6, 1-10. [More Information]
• Chan, C., Weltman, M., Adams, S. (2014). An Uncommon Complication of Percutaneous Endoscopic Gastrostomy Tube Placement. Gastroenterology, 147(2), e3-e4. [More Information]
• Roberts, S., Mitchell, J., Leung, R., Booth, D., Bollipo, S., Ostapowicz, G., Sloss, A., McCaughan, G., Dore, G., Thompson, A., George, J., et al (2014). Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. Journal of Gastroenterology and Hepatology, 29(1), 179-184. [More Information]
• Walker, M., Aggarwal, K., Shim, L., Bassan, M., Kalantar, J., Weltman, M., Jones, M., Powell, N., Talley, N. (2014). Duodenal eosinophilia and early satiety in functional dyspepsia: Confirmation of a positive association in an Australian cohort. Journal of Gastroenterology and Hepatology, 29(3), 474-479. [More Information]
• Milner, K., Jenkins, A., Trenell, M., Tid-Ang, J., Samocha-Bonet, D., Weltman, M., Xu, A., George, J., Chisholm, D. (2014). Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. Journal of Viral Hepatitis, 21(5), 325-332. [More Information]
• Sundaralingam, P., Weltman, M. (2014). Gastrointestinal: pyoderma gangrenosum of the thumb. Journal of Gastroenterology and Hepatology, 29(9), 1659-1659. [More Information]
• O'Connor, K., Ahlenstiel, G., Suppiah, V., Schibeci, S., Ong, A., Leung, R., van der Poorten, D., Douglas, M., Weltman, M., Stewart, G., Liddle, C., George, J., Booth, D. (2014). IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. Innate Immunity, 20(6), 598-605. [More Information]
• Kitson, M., George, J., Dore, G., Leung, R., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., et al (2014). Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. Journal of Gastroenterology and Hepatology, 29, 1458-1462. [More Information]
• Liu, C., Pasupathy, A., Weltman, M. (2014). Multifocal peliosis hepatis simulating metastatic malignancy. Digestive and Liver Disease, 46(9), 862-863. [More Information]
• Gibson, P., Vaizey, C., Black, C., Nicholls, R., Weston, A., Bampton, P., Sparrow, M., Lawrance, I., Selby, W., Weltman, M., et al (2014). Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study. Journal of Crohn's and Colitis, 8(7), 598-606. [More Information]
• Chen, J., Eslick, G., Weltman, M. (2014). Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Alimentary Pharmacology and Therapeutics, 39(2), 117-124. [More Information]
• Suppiah, V., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Irving, W., Stewart, G., George, J., Booth, D., Ahlenstiel, G., et al (2013). CCR5-Delta32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 14(5), 286-290. [More Information]
• Skoien, R., Richardson, M., Jonsson, J., Powell, E., Brunt, E., Neuschwander-Tetri, B., Bhathal, P., Dixon, J., O'Brien, P., Tilg, H., et al (2013). Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver International, 33(4), 624-632. [More Information]
• Walsh, A., Weltman, M., Burger, D., Vivekanandarajah, S., Connor, S., Howlett, M., Radford-Smith, G., Selby, W., Veillard, A., Grimm, M., et al (2013). Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis, 7(10), e449-e456. [More Information]
• Marcellin, P., Cooper, C., Balart, L., Larrey, D., Box, T., Yoshida, E., Lawitz, E., Buggisch, P., Ferenci, P., Weltman, M., et al (2013). Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection. Gastroenterology, 145(4), 790-800. [More Information]
• Kitson, M., Dore, G., George, J., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., Roberts, S. (2013). Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology, 58(3), 467-472. [More Information]
• Crawford, D., Dore, G., Sievert, W., Cheng, W., Weltman, M., McCaughan, G., Rawlinson, W., Marks, P., Yoshihara, M., Rizkalla, B., et al (2012). Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. Antiviral Therapy, 17(5), 849-854. [More Information]
• Gidding, H., Law, M., Amin, J., Ostapowicz, G., Weltman, M., Macdonald, G., Sasadeusz, J., Haber, P., George, J., Dore, G. (2012). Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 196(10), 633-637. [More Information]
• Marcellin, P., Roberts, S., Reddy, K., Harrison, S., Jensen, D., Hadziyannis, S., Diago, M., Weltman, M., Messinger, D., Tatsch, F., et al (2012). Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opinion on Drug Safety, 11(6), 901-909. [More Information]
• Koloski, N., Jones, M., Kalantar, J., Weltman, M., Zaguirre, J., Talley, N. (2012). The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut, 61(9), 1284-1290. [More Information]
• Sasadeusz, J., Dore, G., Kronborg, I., Barton, D., Yoshihara, M., Weltman, M. (2011). Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction, 106(5), 977-984. [More Information]
• Baleriola, C., Rawlinson, W., Dore, G., Chaverot, S., Stelzer-Braid, S., Yoshihara, M., Crawford, D., Sievert, W., McCaughan, G., Weltman, M., et al (2011). Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients. Antiviral Therapy, 16(2), 173-180. [More Information]
• Thomson, A., Kwok, R., Weltman, M. (2011). Genetic evaluation of polyposis. Current Colorectal Cancer Reports, 7(1), 8-15. [More Information]
• Smith, K., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Matthews, G., Irving, W., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine, 3(8), 57-1-57-13. [More Information]
• Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 8(9), e1001092-1-e1001092-8. [More Information]
• Dawes, G., Sitharthan, T., Conigrave, K., Phung, N., Weltman, M. (2011). Patients admitted for inpatient cannabis detoxification: withdrawal symptoms and impacts of common comorbidities. Journal of Substance Use, 16(5), 392-405. [More Information]
• Shim, L., Eslick, G., Simring, A., Murray, H., Weltman, M. (2011). The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). Journal of Crohn's and Colitis, 5(3), 234-238. [More Information]
• Sievert, W., Dore, G., McCaughan, G., Yoshihara, M., Crawford, D., Cheng, W., Weltman, M., Rawlinson, W., Rizkalla, B., DePamphilis, J., et al (2011). Virological Response is Associated with Decline in Hemoglobin Concentration During Pegylated Interferon and Ribavirin Therapy in Hepatitis C Virus Genotype 1. Hepatology, 53(4), 1109-1117. [More Information]
• Milner, K., van der Poorten, D., Trenell, M., Jenkins, A., Xu, A., Smythe, G., Dore, G., Zekry, A., Weltman, M., Fragomeli, V., George, J., et al (2010). Chronic Hepatitis C is Associated with Peripheral rather than Hepatic Insulin Resistance. Gastroenterology, 138(3), 932-941. [More Information]
• Thomson, A., Weltman, M. (2010). Electronic images of the month. Severe duodenitis after massive chronic Ibuprofen overdose. Clinical Gastroenterology and Hepatology, 8(11), e114. [More Information]
• Cheng, W., Roberts, S., McCaughan, G., Sievert, W., Weltman, M., Crawford, D., Rawlinson, W., Marks, P., Thommes, J., Rizkalla, B., et al (2010). Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. Journal of Hepatology, 53(4), 616-623. [More Information]
• Brzozowska, M., Ostapowicz, G., Weltman, M. (2009). An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. Journal of Gastroenterology and Hepatology, 24(2), 243-247. [More Information]
• Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M., Bassendine, M., Spengler, U., Dore, G., Powell, E., Stewart, G., Booth, D., George, J., et al (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics, 41(10), 1100-1104. [More Information]
• Roberts, S., Weltman, M., Crawford, D., McCaughan, G., Sievert, W., Cheng, W., Rawlinson, W., Desmond, P., Marks, P., Yoshihara, M., et al (2009). Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology, 50(4), 1045-1055. [More Information]
• Richardson, K., Baillie, A., Reid, S., Morley, K., Teesson, M., Sannibale, C., Weltman, M., Haber, P. (2008). Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction, 103(6), 953-959. [More Information]
• Razali, K., Thein, H., Bell, J., Cooper-Stanbury, M., Dolan, K., Dore, G., George, J., Kaldore, J., Karvelas, M., Li, J., Weltman, M., et al (2007). Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence, 91(39509), 228-235. [More Information]
• Richardson, M., Jonsson, J., Powell, E., Brunt, E., Neuschwander-Tetri, B., Bhathal, P., Dixon, J., Weltman, M., Tilg, H., Moschen, A., et al (2007). Progressive Fibrosis in Nonalcoholic Steatohepatitis: Association With Altered Regeneration and a Ductular Reaction. Gastroenterology, 133(1), 80-90. [More Information]
• Morley, K., Teesson, M., Reid, S., Sannibale, C., Thomson, C., Phung, N., Weltman, M., Bell, J., Richardson, K., Haber, P. (2006). Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction, 101(10), 1451-1462. [More Information]
• Richardson, K., Reid, S., Morley, K., Teesson, M., Sannibale, C., Weltman, M., Baillie, A., Haber, P. (2006). The effects of alcohol and naltrexone on craving and alcohol consumption. Alcoholism: Clinical and Experimental Research, 30(s2), 169A-169A.
• Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644. [More Information]
• Shaw, D., Williams, R., Cook, I., Wallace, K., Weltman, M., Collins, P., McKay, E., Smart, R., Simula, M. (2004). Oropharyngeal scintigraphy: a reliable technique for the quantitative evaluation of oral-pharyngeal swallowing. Dysphagia, 19(1), 36-42. [More Information]
• Fuller, S., Kumar, P., Weltman, M., Wiley, J. (2003). Autoimmune hemolysis associated with primary biliary cirrhosis responding to ursodeoxycholic acid as sole treatment. American Journal Of Hematology, 72(1), 31-33. [More Information]
• Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. Hepatology, 36(1), 142-149. [More Information]
• Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology, 35(2), 373-379. [More Information]
• Chitturi, S., Abeygunasekera, S., Fung, C., Samarasinghe, D., Lin, R., McDonald, D., Weltman, M., Farrell, G., George, J. (2001). Haemochromatosis gene mutations, hepatic iron content and nonalcoholic steatohepatitis. Hepatology, 19, 1768-1778.

2019

• Nicoll, A., Roberts, S., Lim, R., Mitchell, J., Weltman, M., George, J., Wigg, A., Stuart, K., Gow, P., MacQuillan, G., Strasser, S., et al (2019). Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Alimentary Pharmacology and Therapeutics, 49(10), 1314-1322. [More Information]

2018

• Cunningham, E., Amin, J., Feld, J., Bruneau, J., Dalgard, O., Powis, J., Hellard, M., Cooper, C., Read, P., Weltman, M., et al (2018). Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. International Journal of Drug Policy, 62, 14-23. [More Information]
• Roberts, S., Lim, R., Strasser, S., Nicoll, A., Gazzola, A., Mitchell, J., Siow, W., Khoo, T., Hamarneh, Z., Weltman, M., George, J., et al (2018). Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. Clinical Gastroenterology and Hepatology, 16(2), 268-277. [More Information]
• Mayo, M., Wigg, A., Leggett, B., Arnold, H., Thompson, A., Weltman, M., Carey, E., Muir, A., Ling, L., Rossi, S., et al (2018). NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Hepatology Communications, 2(9), 1037-1050. [More Information]

2017

• Cunningham, E., Hajarizadeh, B., Dalgard, O., Amin, J., Hellard, M., Foster, G., Bruggmann, P., Conway, B., Backmund, M., Weltman, M., et al (2017). Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infectious Diseases, 17(1), 1-12. [More Information]
• Midgard, H., Hajarizadeh, B., Cunningham, E., Conway, B., Backmund, M., Bruggmann, P., Bruneau, J., Bourgeois, S., Dunlop, A., Weltman, M., et al (2017). Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International Journal of Drug Policy, 47, 230-238. [More Information]
• Grebely, J., Dalgard, O., Cunningham, E., Hajarizadeh, B., Foster, G., Bruggmann, P., Conway, B., Backmund, M., Robaeys, G., Weltman, M., et al (2017). Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. International Journal of Drug Policy, 47, 177-186. [More Information]
• Jideh, B., Weltman, M., Wu, Y., Chan, C. (2017). Esophageal squamous papilloma lacks clear clinicopathological associations. World Journal of Clinical Cases, 5(4), 134-139. [More Information]
• Eslam, M., McLeod, D., Kelaeng, K., Mangia, A., Berg, T., Thabet, K., Irving, W., Dore, G., Sheridan, D., Gronbaek, H., Booth, D., Weltman, M., Douglas, M., Liddle, C., George, J., et al (2017). IFN-(lambda)3, not IFN-(lambda)4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nature Genetics, 49(5), 795-800. [More Information]
• Cropley, A., Weltman, M. (2017). The use of immunosuppression in autoimmune hepatitis: A current literature review. Clinical and Molecular Hepatology, 23(1), 22-26. [More Information]

2016

• Eslam, M., Mangia, A., Berg, T., Chan, H., Irving, W., Dore, G., Abate, M., Bugianesi, E., Adams, L., Najim, M., Weltman, M., Rahme, A., Booth, D., Liddle, C., Douglas, M., van der Poorten, D., George, J., White, R., Leung, R., et al (2016). Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 64(1), 34-46. [More Information]
• Eslam, M., Hashem, A., Romero-Gomez, M., Berg, T., Dore, G., Mangia, A., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Kelaeng, K., Ahlenstiel, G., Liddle, C., Douglas, M., Booth, D., George, J., et al (2016). FibroGENE: A gene-based model for staging liver fibrosis. Journal of Hepatology, 64(2), 390-398. [More Information]
• O'Connor, K., Read, S., Wang, X., Schibeci, S., Eslam, M., Ong, A., Weltman, M., Douglas, M., Mazzola, A., Craxi, A., Stewart, G., Liddle, C., George, J., Ahlenstiel, G., Booth, D., et al (2016). IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes and Immunity, 17(6), 328-334. [More Information]
• Jideh, B., Keegan, A., Weltman, M. (2016). Lymphocytic esophagitis: Report of three cases and review of the literature. World Journal of Clinical Cases, 4(12), 413-418. [More Information]
• Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., Irving, W., Berg, T., Dore, G., Gronbaek, H., Sheridan, D., Weltman, M., White, R., Douglas, M., Liddle, C., van der Poorten, D., George, J., Eslam, M., et al (2016). MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 7, 1-8. [More Information]
• Jideh, B., Chen, H., Weltman, M., Chan, C. (2016). Metastatic periampullary clear cell renal carcinoma. Gastrointestinal Endoscopy, 83(5), 1040-1042. [More Information]
• Grebely, J., Alavi, M., Micallef, M., Dunlop, A., Balcomb, A., Phung, N., Weltman, M., Day, C., Treloar, C., Bath, N., Haber, P., et al (2016). Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study. Addiction, 111(2), 311-319. [More Information]

2015

• Fragomeli, V., Weltman, M. (2015). Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care. Journal of Gastroenterology and Hepatology, 30(Suppl 2), 6-11. [More Information]
• Kemp, W., Levy, M., Weltman, M., Lubel, J. (2015). Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. Journal of Gastroenterology and Hepatology, 30(3), 453-462. [More Information]
• Koloski, N., Jones, M., Weltman, M., Kalantar, J., Bone, C., Gowryshankar, A., Walker, M., Talley, N. (2015). Identification of early environmental risk factors for irritable bowel syndrome and dyspepsia. Neurogastroenterology and Motility, 27(9), 1317-1325. [More Information]
• Eslam, M., Hashem, A., Leung, R., Romero-Gomez, M., Berg, T., Dore, G., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Douglas, M., Liddle, C., Booth, D., George, J., Ahlenstiel, G., et al (2015). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 6, 1-10. [More Information]

2014

• Chan, C., Weltman, M., Adams, S. (2014). An Uncommon Complication of Percutaneous Endoscopic Gastrostomy Tube Placement. Gastroenterology, 147(2), e3-e4. [More Information]
• Roberts, S., Mitchell, J., Leung, R., Booth, D., Bollipo, S., Ostapowicz, G., Sloss, A., McCaughan, G., Dore, G., Thompson, A., George, J., et al (2014). Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. Journal of Gastroenterology and Hepatology, 29(1), 179-184. [More Information]
• Walker, M., Aggarwal, K., Shim, L., Bassan, M., Kalantar, J., Weltman, M., Jones, M., Powell, N., Talley, N. (2014). Duodenal eosinophilia and early satiety in functional dyspepsia: Confirmation of a positive association in an Australian cohort. Journal of Gastroenterology and Hepatology, 29(3), 474-479. [More Information]
• Milner, K., Jenkins, A., Trenell, M., Tid-Ang, J., Samocha-Bonet, D., Weltman, M., Xu, A., George, J., Chisholm, D. (2014). Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. Journal of Viral Hepatitis, 21(5), 325-332. [More Information]
• Sundaralingam, P., Weltman, M. (2014). Gastrointestinal: pyoderma gangrenosum of the thumb. Journal of Gastroenterology and Hepatology, 29(9), 1659-1659. [More Information]
• O'Connor, K., Ahlenstiel, G., Suppiah, V., Schibeci, S., Ong, A., Leung, R., van der Poorten, D., Douglas, M., Weltman, M., Stewart, G., Liddle, C., George, J., Booth, D. (2014). IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. Innate Immunity, 20(6), 598-605. [More Information]
• Kitson, M., George, J., Dore, G., Leung, R., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., et al (2014). Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. Journal of Gastroenterology and Hepatology, 29, 1458-1462. [More Information]
• Liu, C., Pasupathy, A., Weltman, M. (2014). Multifocal peliosis hepatis simulating metastatic malignancy. Digestive and Liver Disease, 46(9), 862-863. [More Information]
• Gibson, P., Vaizey, C., Black, C., Nicholls, R., Weston, A., Bampton, P., Sparrow, M., Lawrance, I., Selby, W., Weltman, M., et al (2014). Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study. Journal of Crohn's and Colitis, 8(7), 598-606. [More Information]
• Chen, J., Eslick, G., Weltman, M. (2014). Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Alimentary Pharmacology and Therapeutics, 39(2), 117-124. [More Information]

2013

• Suppiah, V., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Irving, W., Stewart, G., George, J., Booth, D., Ahlenstiel, G., et al (2013). CCR5-Delta32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 14(5), 286-290. [More Information]
• Skoien, R., Richardson, M., Jonsson, J., Powell, E., Brunt, E., Neuschwander-Tetri, B., Bhathal, P., Dixon, J., O'Brien, P., Tilg, H., et al (2013). Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver International, 33(4), 624-632. [More Information]
• Walsh, A., Weltman, M., Burger, D., Vivekanandarajah, S., Connor, S., Howlett, M., Radford-Smith, G., Selby, W., Veillard, A., Grimm, M., et al (2013). Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis, 7(10), e449-e456. [More Information]
• Marcellin, P., Cooper, C., Balart, L., Larrey, D., Box, T., Yoshida, E., Lawitz, E., Buggisch, P., Ferenci, P., Weltman, M., et al (2013). Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection. Gastroenterology, 145(4), 790-800. [More Information]
• Kitson, M., Dore, G., George, J., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., Roberts, S. (2013). Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology, 58(3), 467-472. [More Information]

2012

• Crawford, D., Dore, G., Sievert, W., Cheng, W., Weltman, M., McCaughan, G., Rawlinson, W., Marks, P., Yoshihara, M., Rizkalla, B., et al (2012). Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. Antiviral Therapy, 17(5), 849-854. [More Information]
• Gidding, H., Law, M., Amin, J., Ostapowicz, G., Weltman, M., Macdonald, G., Sasadeusz, J., Haber, P., George, J., Dore, G. (2012). Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 196(10), 633-637. [More Information]
• Marcellin, P., Roberts, S., Reddy, K., Harrison, S., Jensen, D., Hadziyannis, S., Diago, M., Weltman, M., Messinger, D., Tatsch, F., et al (2012). Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opinion on Drug Safety, 11(6), 901-909. [More Information]
• Koloski, N., Jones, M., Kalantar, J., Weltman, M., Zaguirre, J., Talley, N. (2012). The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut, 61(9), 1284-1290. [More Information]

2011

• Sasadeusz, J., Dore, G., Kronborg, I., Barton, D., Yoshihara, M., Weltman, M. (2011). Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction, 106(5), 977-984. [More Information]
• Baleriola, C., Rawlinson, W., Dore, G., Chaverot, S., Stelzer-Braid, S., Yoshihara, M., Crawford, D., Sievert, W., McCaughan, G., Weltman, M., et al (2011). Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients. Antiviral Therapy, 16(2), 173-180. [More Information]
• Thomson, A., Kwok, R., Weltman, M. (2011). Genetic evaluation of polyposis. Current Colorectal Cancer Reports, 7(1), 8-15. [More Information]
• Smith, K., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Matthews, G., Irving, W., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine, 3(8), 57-1-57-13. [More Information]
• Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 8(9), e1001092-1-e1001092-8. [More Information]
• Dawes, G., Sitharthan, T., Conigrave, K., Phung, N., Weltman, M. (2011). Patients admitted for inpatient cannabis detoxification: withdrawal symptoms and impacts of common comorbidities. Journal of Substance Use, 16(5), 392-405. [More Information]
• Weltman, M., Phung, N. (2011). Rectal/perianal mass and colorectal cancer. In N. J. Talley (Eds.), Clinical Gastroenterology, 3rd Edition, (pp. 279-292). Australia: Elsevier.
• Shim, L., Eslick, G., Simring, A., Murray, H., Weltman, M. (2011). The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). Journal of Crohn's and Colitis, 5(3), 234-238. [More Information]
• Sievert, W., Dore, G., McCaughan, G., Yoshihara, M., Crawford, D., Cheng, W., Weltman, M., Rawlinson, W., Rizkalla, B., DePamphilis, J., et al (2011). Virological Response is Associated with Decline in Hemoglobin Concentration During Pegylated Interferon and Ribavirin Therapy in Hepatitis C Virus Genotype 1. Hepatology, 53(4), 1109-1117. [More Information]
• Weltman, M., Phung, N. (2011). Vomiting blood, stack stools, blood per rectum, occult bleeding. In N. J. Talley (Eds.), Clinical Gastroenterology, 3rd Edition, (pp. 115-129). Australia: Elsevier.

2010

• Milner, K., van der Poorten, D., Trenell, M., Jenkins, A., Xu, A., Smythe, G., Dore, G., Zekry, A., Weltman, M., Fragomeli, V., George, J., et al (2010). Chronic Hepatitis C is Associated with Peripheral rather than Hepatic Insulin Resistance. Gastroenterology, 138(3), 932-941. [More Information]
• Thomson, A., Weltman, M. (2010). Electronic images of the month. Severe duodenitis after massive chronic Ibuprofen overdose. Clinical Gastroenterology and Hepatology, 8(11), e114. [More Information]
• Cheng, W., Roberts, S., McCaughan, G., Sievert, W., Weltman, M., Crawford, D., Rawlinson, W., Marks, P., Thommes, J., Rizkalla, B., et al (2010). Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. Journal of Hepatology, 53(4), 616-623. [More Information]

2009

• Milne, B., Bell, J., Weltman, M., Lampropoulos, B., Towns, S. (2009). Alcohol, drugs and Australian young people. In Bennet, D; Towns, S; Elliot, E; Merrick, J. (Eds.), Challenges in Adolescent Health: An Australian Perspective, (pp. 163-175). United States: Nova Science Publishers.
• Brzozowska, M., Ostapowicz, G., Weltman, M. (2009). An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. Journal of Gastroenterology and Hepatology, 24(2), 243-247. [More Information]
• Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M., Bassendine, M., Spengler, U., Dore, G., Powell, E., Stewart, G., Booth, D., George, J., et al (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics, 41(10), 1100-1104. [More Information]
• Roberts, S., Weltman, M., Crawford, D., McCaughan, G., Sievert, W., Cheng, W., Rawlinson, W., Desmond, P., Marks, P., Yoshihara, M., et al (2009). Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology, 50(4), 1045-1055. [More Information]

2008

• Weltman, M., Darke, J. (2008). Acute liver failure. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 491-501). Australia: Elsevier.
• Richardson, K., Baillie, A., Reid, S., Morley, K., Teesson, M., Sannibale, C., Weltman, M., Haber, P. (2008). Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction, 103(6), 953-959. [More Information]
• Talley, N., Segal, I., Weltman, M. (2008). Gastroenterology and Hepatology: a clinical handbook. Australia: Elsevier.
• Weltman, M. (2008). Obesity and Abnormal Liver Function Tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 411-420). Australia: Elsevier.
• Weltman, M. (2008). Occult gastrointestinal bleeding and iron deficiency anemia. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 246-259). Australia: Elsevier.

2007

• Razali, K., Thein, H., Bell, J., Cooper-Stanbury, M., Dolan, K., Dore, G., George, J., Kaldore, J., Karvelas, M., Li, J., Weltman, M., et al (2007). Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence, 91(39509), 228-235. [More Information]
• Richardson, M., Jonsson, J., Powell, E., Brunt, E., Neuschwander-Tetri, B., Bhathal, P., Dixon, J., Weltman, M., Tilg, H., Moschen, A., et al (2007). Progressive Fibrosis in Nonalcoholic Steatohepatitis: Association With Altered Regeneration and a Ductular Reaction. Gastroenterology, 133(1), 80-90. [More Information]

2006

• Morley, K., Teesson, M., Reid, S., Sannibale, C., Thomson, C., Phung, N., Weltman, M., Bell, J., Richardson, K., Haber, P. (2006). Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction, 101(10), 1451-1462. [More Information]
• Richardson, K., Reid, S., Morley, K., Teesson, M., Sannibale, C., Weltman, M., Baillie, A., Haber, P. (2006). The effects of alcohol and naltrexone on craving and alcohol consumption. Alcoholism: Clinical and Experimental Research, 30(s2), 169A-169A.

2004

• Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644. [More Information]
• Shaw, D., Williams, R., Cook, I., Wallace, K., Weltman, M., Collins, P., McKay, E., Smart, R., Simula, M. (2004). Oropharyngeal scintigraphy: a reliable technique for the quantitative evaluation of oral-pharyngeal swallowing. Dysphagia, 19(1), 36-42. [More Information]

2003

• Fuller, S., Kumar, P., Weltman, M., Wiley, J. (2003). Autoimmune hemolysis associated with primary biliary cirrhosis responding to ursodeoxycholic acid as sole treatment. American Journal Of Hematology, 72(1), 31-33. [More Information]

2002

• Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. Hepatology, 36(1), 142-149. [More Information]
• Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology, 35(2), 373-379. [More Information]

2001

• Chitturi, S., Abeygunasekera, S., Fung, C., Samarasinghe, D., Lin, R., McDonald, D., Weltman, M., Farrell, G., George, J. (2001). Haemochromatosis gene mutations, hepatic iron content and nonalcoholic steatohepatitis. Hepatology, 19, 1768-1778.